[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nutrition-related-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nutrition-related-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100525092","reducing-metabolic-dysregulation-in-dyads-100525092",false,"NCT06117241","Reducing Metabolic Dysregulation in Dyads","A Transdisciplinary Approach to Investigating Metabolic and Risk of Early-Onset Colorectal Cancer: A Randomized Intervention Trial in Human Dyads and Mechanistic Study in Animals","REMEDY","Individuals eligible to participate in this study will be apparently disease- free, obese (BMI ≥ 30kg\u002Fm2) AAs or EAs who have self-identified a partner who is at least 9 years old, with whom they live and who also is at least overweight. Each index patient will: 1) Be AA or EA by self-report; 2) Be ≤55 years old; 3) Have agreed to undergo colonoscopy screening and found to have ≥1 polyp(s) that place them at elevated risk for future adenomas and CRC; 4) Be free of co-morbid conditions or other factors that would limit participation in this trial; 5) Have a BMI ≥30kg\u002Fm2; 6) Be willing to commit to investing the time and effort required to participate in this trial (i.e., willing to complete all assessments and provide biological samples as specified in the consent); and 7) Have no recent antibiotic use (≤3 months). Their dyad partner needs to: 1) Be at least 9 years old; 2) Live in the same household and consumes meals together; 3) Be at least overweight; 4) Agree to all study procedures, including provision of biological samples, anthropometric measurements, and self-reported dietary and other assessments; 5) Have no recent antibiotic use (≤3 months).",true,"ALL","9 Years","55 Years",{"count":22,"type":23},180,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is a 6-month randomized controlled trail of diet modification designed to reduce chronic inflammation and reverse metabolic dysfunction among obese individuals with one or more polyps found at a colonoscopy screening. We also will recruit an at least overweight partner, who lives in the same household. To be eligible, participants will be apparently disease-free, obese AAs or EAs who have self-identified a partner who is at least 9 years, with whom they live and who also is at least overweight. Each index participant will: 1) Be AA or EA by self-report; 2) Be ≤55 years old; 3) Have undergone a colonoscopy screening and found to have ≥1 polyp(s); 4) Be free of co-morbid conditions or other factors that would limit participation in this trial; 5) Have a BMI ≥30kg\u002Fm2; 6) Be willing to commit to investing the time and effort required to participate in this trial (i.e., willing to complete all assessments and provide biological samples as specified in the consent); and 7) Have no recent antibiotic use. Their partner needs to: 1) Be at least 9 years old; 2) Live in the same household and consumes meals together; 3) Be at least overweight; 4) Agree to all study procedures, including provision of biological samples, body measurements, and self-reported dietary and other assessments; and 5) Have no recent antibiotic use.",[29,30,31],"Colorectal Cancer","Inflammation","Nutrition Related Cancer",[33,34,35,36],"Body Composition","Cancer","Digestive System","Microbiome","RECRUITING","2026-01-27",{"date":40,"type":41},"2026-01-29","ACTUAL",{"date":43,"type":41},"2023-10-17",{"date":45,"type":23},"2028-03-31",{"name":47,"class":48},"University of South Carolina","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100539785","colorectal-cancer-dataset-in-xijing-hospital-from-2011-100539785","NCT06308354","Colorectal Cancer Dataset in Xijing Hospital From 2011","Inclusion Criteria:\n\n* 1\\. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;\n* 2\\. Visit our center with complete medical records and pathological information;\n* 3\\. Colorectal cancer patients diagnosed between 2013 and 2023.\n\nExclusion Criteria:\n\n* 1\\. The patient has other colorectal malignancies other than adenocarcinoma;\n* 2\\. Malignant tumors adjacent to organs invading the colon and rectum;\n* 3\\. Malignant tumors from distant organs metastasize to the colon and rectum;\n* 4\\. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.","18 Years","100 Years",{"count":59,"type":23},40000,"10 Years","OBSERVATIONAL","To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.",[64,65,31],"Prognostic Cancer Model","Chemotherapy","2024-03-11",{"date":68,"type":41},"2024-03-13",{"date":70,"type":41},"2011-01-01",{"date":72,"type":23},"2048-01-01",{"name":74,"class":48},"Xijing Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100512959","effect-of-exercise-and-enteral-nutrition-on-survival-100512959","NCT05959226","Effect of Exercise and Enteral Nutrition on Survival","Effect of Exercise and Enteral Nutrition Intervention on Survival in Patients With Locally Advanced Gastric Cancer: a Prospective Multicenter Randomized Controlled Study","ENERGY","Inclusion Criteria:（1) 18 years ≤ age ≤ 70 years (2) Preoperative Karnofsky physical condition score: 0 or 1 or 2 (3) Preoperative pathological biopsy by gastroscope, histologically confirmed as adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma, mixed adenocarcinoma) (4) Gastric cancer patients diagnosed with clinical stage Ib IIIc through CT, MRI, gastroscopy, and pathology (based on the 8th edition of UICC\u002FAJCC staging) (5) Abdominal enhanced CT\u002FMRI examination showed a clinical staging of cT2-4aN0-3M0 (based on AJCC-8thTNM tumor staging), and standard D2 radical surgery for gastric cancer was performed; (6) Have not received any radiotherapy, chemotherapy or immunotherapy; (7) Hemoglobin ≥ 80g\u002FL; (8) Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; (9) Platelets ≥ 75 × 109\u002FL; (10) ALT ≤ 2.5 times the normal upper limit value; (11) AST ≤ 2.5 times the normal upper limit value; (12) ALP ≤ 2.5 times the normal upper limit value; (13) Serum total bilirubin\\\u003C1.5 times the upper normal limit value; (14) Serum creatinine\\\u003C1 times the upper normal limit value; (15) Sign written informed consent;\n\nExclusion Criteria:\n\n1. Patients diagnosed with distant metastasis through abdominal lung CT\u002FMRI or PET-CT\n2. Pregnant or lactating women\n3. People with uncontrolled epilepsy, Central nervous system disease or mental disorders\n4. Patients with combined limb disabilities or motor dysfunction;\n5. Patients with other malignant diseases in the past five years, excluding cured skin cancer and cervical Carcinoma in situ\n6. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring medication intervention, or a history of myocardial infarction within the past 6 months\n7. Have a history of cerebral infarction or cerebral hemorrhage in the past 6 months\n8. Organ transplantation requires immunosuppressive therapy\n9. Serious uncontrolled recurrent infections or other serious uncontrolled concomitant diseases\n10. The patient has complications of Grade III or above in Clavien Dindo classification or has been hospitalized for more than 14 days after surgery due to various reasons;\n11. Urgent surgery required due to tumor emergencies (bleeding, perforation, obstruction)\n12. Pulmonary function test FEV1\\\u003Cexpected value 50%\n13. Received radiotherapy, chemotherapy, or other neoadjuvant treatment before surgery","70 Years",{"count":85,"type":23},960,[26],"The present clinical trial was designed to explore the effect of postoperative physical exercise combined with enteral nutritional supplement on 3-year disease-free survival in patients with advanced gastric cancer.",[89,31,90],"Gastric Cancer","Sarcopenia","NOT_YET_RECRUITING","2023-07-17",{"date":94,"type":41},"2023-07-25",{"date":96,"type":23},"2023-08-01",{"date":98,"type":23},"2028-08-01",{"name":100,"class":48},"The First Hospital of Jilin University"]